Grauer & Weil
GRAUWEIL NSE
Grauer & Weil
ChemicalsNSE: GRAUWEIL BSE: 505710 Commodity Chemicals
Key Fundamentals
MicrocapCommodity ChemicalsChemicalsMarket Cap
₹3,415 Cr
Volatility
Moderate
P/E Ratio
21.42
EBITDA
₹243 Cr
Return on Equity
15.16%
Debt to Equity
0.01
Book Value
₹23.86
52W High
₹87.4
52W Low
₹62.09
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company is almost debt free.
Growth Rate
Revenue Growth
5.07% lower than
3Y
Net Income Growth
4.33% lower than
3Y
Cash Flow Change
5.44% higher than
3Y
ROE
-9.44% lower than
3Y
ROCE
-9.73% higher than
3Y
EBITDA Margin (Avg.)
-1.46% higher than
3Y
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 69d agoAI opinion · based on fundamentals
Risk medium
Grauer & Weil (India) Ltd is a nearly debt-free specialty chemicals and surface finishing company with a market cap of ₹3,695 Cr trading at a PE of 23x. The company has delivered consistent ROE of 16-18% over the past decade but is experiencing a slowdown in sales growth (TTM at 5%) and a significant deterioration in working capital efficiency.
Bull Case 7
- Company is almost debt free, giving it significant financial flexibility and resilience during downturns
- Consistent ROE track record of 16-18% over 3, 5, and 10-year periods indicates disciplined capital allocation
- Compounded profit growth of 20% over 5 years outpaces sales growth of 14%, reflecting improving margins and operating leverage
- 10-year stock CAGR of 18% demonstrates sustained long-term value creation for shareholders
- Price-to-book ratio of 3.49x is reasonable for a debt-free company delivering 16% ROE consistently
- 10-year compounded sales growth of 11% shows the company has scaled revenues meaningfully over a full business cycle
- Dividend yield of 0.6% provides a modest income floor while the company retains earnings for growth
Bear Case 8
- Stock has declined 20% over the past 1 year, significantly underperforming broader markets
- Working capital days have nearly doubled from 53.6 days to 94.7 days, indicating deteriorating cash conversion and potential inventory or receivables stress
- TTM sales growth has decelerated sharply to just 5% compared to 14% over 5 years and 11% over 10 years
- ROE has dipped to 16% in the last year from 18% over 3 years, suggesting early signs of return compression
- TTM profit growth of only 7% is well below the 5-year CAGR of 20%, showing a marked deceleration in earnings momentum
- 3-year sales CAGR of just 7% compared to 5-year CAGR of 14% indicates the growth slowdown is a multi-quarter trend, not a one-off
- PE of 23x may not be justified if the current single-digit growth trajectory persists, as it prices in higher growth expectations
- Small market cap of ₹3,695 Cr in the commodities sector exposes the company to higher cyclical and liquidity risks
This is AI-generated analysis, not financial advice. Do your own due diligence.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 200 | 250 | 285 | 333 | 264 | 255 | 275 | 340 | 253 | 291 | 291 | 355 | 299 |
| Expenses | 152 | 202 | 230 | 294 | 200 | 212 | 222 | 311 | 201 | 248 | 252 | 296 | 251 |
| Operating Profit | 48 | 49 | 55 | 39 | 64 | 43 | 52 | 30 | 53 | 43 | 39 | 59 | 48 |
| OPM % | 24% | 20% | 19% | 12% | 24% | 17% | 19% | 9% | 21% | 15% | 13% | 17% | 16% |
| Other Income | 6 | 7 | 9 | 8 | 8 | 14 | 12 | 12 | 13 | 11 | 12 | 13 | 12 |
| Interest | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| PBT | 48 | 51 | 58 | 39 | 67 | 51 | 58 | 34 | 58 | 48 | 44 | 65 | 54 |
| Tax % | 23% | 26% | 26% | 26% | 24% | 26% | 26% | 25% | 25% | 20% | 26% | 24% | 26% |
| Net Profit | 37 | 37 | 43 | 29 | 51 | 38 | 43 | 26 | 44 | 39 | 32 | 50 | 40 |
| EPS in Rs | 0.81 | 0.83 | 0.94 | 0.64 | 1.12 | 0.83 | 0.95 | 0.57 | 0.96 | 0.85 | 0.71 | 1.09 | 0.88 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 409 | 413 | 432 | 497 | 600 | 618 | 605 | 768 | 981 | 1,068 | 1,133 | 1,190 | 1,236 |
| Expenses | 333 | 335 | 346 | 400 | 494 | 521 | 505 | 655 | 825 | 877 | 944 | 996 | 1,047 |
| Operating Profit | 76 | 78 | 86 | 98 | 106 | 97 | 101 | 114 | 156 | 191 | 189 | 194 | 189 |
| OPM % | 19% | 19% | 20% | 20% | 18% | 16% | 17% | 15% | 16% | 18% | 17% | 16% | 15% |
| Other Income | 1 | 2 | 4 | 10 | 5 | 20 | 15 | 16 | 18 | 31 | 47 | 50 | 49 |
| Interest | 14 | 10 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 2 |
| Depreciation | 16 | 14 | 14 | 15 | 15 | 19 | 18 | 20 | 20 | 21 | 22 | 24 | 25 |
| PBT | 46 | 56 | 73 | 91 | 94 | 95 | 94 | 107 | 152 | 196 | 210 | 216 | 211 |
| Tax % | 28% | 24% | 26% | 30% | 32% | 21% | 27% | 26% | 26% | 25% | 25% | 24% | — |
| Net Profit | 33 | 42 | 54 | 64 | 64 | 76 | 69 | 79 | 113 | 146 | 157 | 164 | 160 |
| EPS in Rs | 0.74 | 0.93 | 1.2 | 1.41 | 1.41 | 1.67 | 1.52 | 1.74 | 2.49 | 3.23 | 3.47 | 3.62 | 3.53 |
| Div. Payout % | 15% | 15% | 17% | 21% | 21% | 15% | 16% | 19% | 16% | 8% | 14% | 28% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 45 | 45 |
| Reserves | 194 | 228 | 278 | 331 | 379 | 422 | 491 | 560 | 657 | 783 | 894 | 1,036 |
| Borrowings | 68 | 27 | 20 | 7 | 21 | 23 | 22 | 25 | 24 | 27 | 12 | 15 |
| Other Liabilities | 125 | 119 | 133 | 146 | 159 | 174 | 214 | 217 | 251 | 292 | 334 | 349 |
| Total Liabilities | 410 | 397 | 454 | 507 | 581 | 642 | 750 | 824 | 954 | 1,124 | 1,286 | 1,445 |
| Fixed Assets | 216 | 210 | 212 | 206 | 231 | 241 | 238 | 247 | 244 | 243 | 254 | 277 |
| CWIP | 0 | 0 | 0 | 0 | 3 | 1 | 4 | 1 | 3 | 14 | 27 | 37 |
| Investments | 2 | 1 | 1 | 3 | 1 | 0 | 0 | 1 | 17 | 49 | 71 | 443 |
| Other Assets | 192 | 186 | 241 | 297 | 346 | 399 | 508 | 576 | 690 | 817 | 934 | 688 |
| Total Assets | 410 | 397 | 454 | 507 | 581 | 642 | 750 | 824 | 954 | 1,124 | 1,286 | 1,445 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 55 | 77 | 87 | 71 | 33 | 84 | 117 | 44 | 114 | 160 | 144 | 152 |
| Investing | -9 | -8 | -54 | -61 | -13 | -53 | -43 | -17 | -116 | -109 | -120 | -184 |
| Financing | -46 | -62 | -10 | -25 | -2 | -36 | -3 | -15 | -19 | -20 | -42 | -28 |
| Net Cash Flow | 0 | 8 | 23 | -14 | 17 | -5 | 71 | 12 | -21 | 31 | -19 | -60 |
| Free Cash Flow | 45 | 69 | 72 | 62 | -12 | 62 | 102 | 22 | 95 | 128 | 105 | 100 |
| CFO/OP | 83 | 114 | 120 | 94 | 63 | 110 | 132 | 72 | 98 | 107 | 105 | 98 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 70 | 63 | 65 | 68 | 67 | 77 | 62 | 68 | 63 | 64 | 54 |
| Inventory Days | 120 | 115 | 118 | 100 | 106 | 126 | 108 | 121 | 83 | 90 | 98 | 112 |
| Days Payable | 67 | 68 | 82 | 81 | 68 | 95 | 110 | 91 | 77 | 86 | 90 | 99 |
| Cash Conversion Cycle | 133 | 117 | 99 | 83 | 106 | 99 | 75 | 92 | 75 | 68 | 72 | 67 |
| Working Capital Days | 26 | 50 | 38 | 49 | 56 | 57 | 36 | 49 | 43 | 34 | 32 | 27 |
| ROCE % | 21% | 24% | 25% | 27% | 26% | 20% | 19% | 19% | 24% | 26% | 23% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Grauer & Weil insights
64 extracted metrics + investor summaries across FY07–FY26.
Documents
1
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Apr - Regulation 74(5) compliance certificate for quarter ended March 31, 2026. 10 Apr - Regulation 74(5) compliance certificate for quarter ended March 31, 2026.
4
Closure of Trading Window
26 Mar - Trading window closed Apr 1, 2026 until 48 hours after Q4 results for quarter ended Mar 31, 2026. 26 Mar - Trading window closed Apr 1, 2026 until 48 hours after Q4 results for quarter ended Mar 31, 2026.
5
Announcement under Regulation 30 (LODR)-Credit Rating
24 Mar - CARE reaffirmed AA- Stable (LT) on Rs140cr and A1+ (ST) on Rs45cr, March 23-24, 2026. 24 Mar - CARE reaffirmed AA- Stable (LT) on Rs140cr and A1+ (ST) on Rs45cr, March 23-24, 2026.
Frequently Asked Questions about Grauer & Weil
What does Grauer & Weil (India) Ltd do?
Incorporated in 1957, Grauer & Weil
(India) Ltd manufactures and sells
Surface Finishings besides being
in Engineering and Mall business[1]
Where is Grauer & Weil (India) Ltd (GRAUWEIL) listed?
Grauer & Weil (India) Ltd trades as GRAUWEIL on the NSE and under code 505710 on the BSE.
Which sector does Grauer & Weil (India) Ltd belong to?
Grauer & Weil (India) Ltd is classified under the Chemicals sector, in the Commodity Chemicals industry.
What is the market capitalisation of Grauer & Weil (India) Ltd?
Grauer & Weil (India) Ltd has a market capitalisation of ₹3,415 Cr, which places it in the Small Cap band.
What is the PE ratio of Grauer & Weil (India) Ltd?
Grauer & Weil (India) Ltd trades at a PE ratio of 21.42, against a book value of ₹23.86 per share.
What is the 52-week high and low of Grauer & Weil (India) Ltd?
Over the last 52 weeks Grauer & Weil (India) Ltd has traded between ₹62.09 and ₹87.4.
Does Grauer & Weil (India) Ltd pay dividends?
Grauer & Weil (India) Ltd has a dividend yield of 0.65%.
What is the Return on Equity (ROE) of Grauer & Weil (India) Ltd?
Grauer & Weil (India) Ltd reported a return on equity of 15.16%. Its debt-to-equity ratio is 0.01.
Company Information
Incorporated in 1957, Grauer & Weil (India) Ltd manufactures and sells Surface Finishings besides being in Engineering and Mall business[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/GRAUWEIL.md for Grauer & Weil (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.